Importantly, the ImmuScore captured functional drug-response patterns: patients with low scores displayed significantly higher Z-scores-indicating reduced sensitivity across multiple chemotherapeutic and targeted agents.<h4>Discussion</h4>These findings link immunophenotypic signatures to therapeutic vulnerability, providing a mechanistic explanation for treatment failure in a subset of <i>ASXL1</i>-mutated AML. This evidence concerns the gene ASXL1 and acute myeloid leukemia.